Phaseline

Companies › Sichuan Luzhou Buchang Biopharmaceutical

Sichuan Luzhou Buchang Biopharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BC008-1A–Phase 1Glioma; Advanced Esophageal CancersDec 2026
BC001
G protein-coupled receptor β1 autoantibody antagonist
–Phase 1Advanced or Metastatic Gastric CancerApr 2027
Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 1Advanced or Metastatic Gastric CancerApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06773481BC008-1APhase 1GliomaOncologyDec 2026
NCT06773312BC001Phase 1Advanced or Metastatic Gastric CancerOncologyApr 2027
NCT06773312SintilimabPhase 1Advanced or Metastatic Gastric CancerOncologyApr 2027
NCT06773507BC008-1APhase 1Advanced Esophageal CancersOncologyJun 2027

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.